NCT03105947 (COB) is a NA clinical trial of Coconut oil in Cardiovascular Risk Factor, sponsored by University of Cambridge.

Who is sponsoring NCT03105947?

NCT03105947 is sponsored by University of Cambridge.

What drugs are being tested in NCT03105947?

Interventions in NCT03105947: Coconut oil, Butter, Olive oil.

What condition does NCT03105947 study?

NCT03105947 studies Cardiovascular Risk Factor.

Is NCT03105947 still recruiting?

NCT03105947 is currently completed. Last updated 27 October 2017.

Last reviewed 2017-10-27 · How we verify

NCT03105947: COB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Different Dietary Fats on Blood Lipids and Metabolic Measures in Healthy Participants

Completed NA Last updated 27 October 2017

What this trial tests

NA trial testing Coconut oil in Cardiovascular Risk Factor in 94 participants. Completed in 10 August 2017.

Timeline

22 June 2017

Primary endpoint
27 July 2017

10 August 2017

Quick facts

Lead sponsor	University of Cambridge
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	94
Start date	22 June 2017
Primary completion	27 July 2017
Estimated completion	10 August 2017
Sites	1 location across United Kingdom

Drugs / interventions tested

Coconut oil
Butter
Olive oil — full drug profile →

Conditions studied

Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →

Sponsor

University of Cambridge

Who can join

Adults 50 to 75, any sex, with Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomised trial in which healthy volunteers, men and women aged 50-75 years from the general community are randomized into one of three arms: participants will be provided with 50 gm extra virgin coconut oil,or 50 grams butter or 50 extra virgin olive oil to be eaten daily for a month. The key outcome is blood low density lipoprotein cholesterol concentrations and secondary outcomes blood lipid profile (total cholesterol, high density lipoprotein cholesterol, triglycerides) and anthropometric measures: weight and waist circumference. This trial is powered to detect a difference of 0.5 mmol/L LDL-cholesterol difference between the trial arms.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women.
Khaw KT, Sharp SJ, Finikarides L, Afzal I, et al · · 2018 · cited 118× · PMID 29511019 · DOI 10.1136/bmjopen-2017-020167
Extra Virgin Olive Oil: Lesson from Nutrigenomics.
De Santis S, Cariello M, Piccinin E, Sabbà C, et al · · 2019 · cited 59× · PMID 31487787 · DOI 10.3390/nu11092085
Effects of coconut oil, olive oil, and butter on plasma fatty acids and metabolic risk factors: a randomized trial.
Sowah SA, Koulman A, Sharp SJ, Imamura F, et al · · 2024 · cited 2× · PMID 39490924 · DOI 10.1016/j.jlr.2024.100681

Verify or expand the search:

Other trials of Coconut oil

Trials testing the same drug.

NCT07100145 — Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus · Phase 4 · not yet recruiting
NCT06640036 — FILIP: Fat Intake, Inflammation and LIPids · NA · completed
NCT07175090 — Evaluation of Coconut Oil Mouth Rinse on Periodontal Parameters · EARLY_PHASE1 · completed
NCT05539742 — Comparison of the Effect of MCFA and LCFA on Postprandial Appetite and Lipemia · NA · completed
NCT04842786 — Topical Coconut Oil Application and Incidence of Sepsis in Neonates · NA · unknown

Other recruiting trials for Cardiovascular Risk Factor

Currently open trials in the same condition.

NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
NCT05887622 — The Potassium Supplementation Study · NA · recruiting
NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting

Other University of Cambridge trials

Trials by the same sponsor.

NCT07106216 — Evaluating Near-infrared Spectroscopy Devices for Monitoring Traumatic Brain Injury · not yet recruiting
NCT07341230 — Deep Brain Stimulation to Understand and Treat Addiction · NA · recruiting
NCT07154836 — Call for Life: Exploring mHealth Solutions for Enhancing Childhood Vaccinations Among Displaced Children in Conflict-aff · NA · enrolling by invitation
NCT06844539 — taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs · NA · recruiting
NCT07026656 — Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-assoc · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03105947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cambridge
Last refreshed: 27 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03105947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing